Results: Biomarkers of joint tissue turnover, cytokines, chemokines and peptide arrays were measured in different cohorts and studies. Amongst those were previously tested biomarkers such as osteocalcin, Carboxy-terminal cross-linked fragment of type II collagen (CTX-II) and cartilage oligomeric matrix protein (COMP). A majority of the biomarker were classified as I, B or B biomarkers according to the BIPED criteria. Work is continuing on testing biomarkers in OA. There is still a huge, unmet medical need to identify, test, validate and qualify novel and well-known biomarkers. A pre-requisite for this is better characterization and classification of biomarkers to their needs, which may not be reached before higher understanding of OA phenotypes has been gained. In addition, we provide some references to some recent guidelines from Food and Drug Administration (FDA) and European Medicines Agency (EMA) on qualification and usage of biomarkers for drug development and personalized medicine, which may provide value to the field.
Introduction
There is still a need for biomarkers in osteoarthritis (OA) for diagnosis, prognosis and monitoring of disease activity in clinical practice, as well as biomarkers for patient selection and study design optimization in clinical interventional trials 1 . To date limited biomarkers have been approved by the regulatory authorities for theses uses in OA; however multiple biomarkers have been developed and tested over the last decades. Also, in 2014, new biomarkers were investigated, alongside evaluation of well-known biomarkers.
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA), have recently published different guidelines recommending a higher level of integration of biomarkers in the development and testing of new drugs to advance decision-making on dosing, time and treatment effect, trial design, and risk/benefit analysis and personalized medicine (please see references at the end of the article) It is believed that by implementing biomarkers for screening of drug candidates in early clinical development (e.g., in vitro and/or pre-clinically), potential safety issues can be addressed in advance, and hence increase the drug development efficiency, and possibly reduce the overall cost of running and OA clinical trial 2 . The primary objective of using biomarkers in drug development is to identify a sub-population of responsive subjects that will provide best evidence for rejecting the null hypothesis of no treatment effect, and thereby demonstrate the efficacy and the safety of a drug candidate. Since biomarkers are considered as objective measures of biological, pathological or pharmacological events, the probability of false positives and false negatives selection becomes reduced compared to patient recruitment based on objective measures such as Visual analog score (VAS) pain. Consequently, the power calculation for future clinical trials will result in a smaller sample size.
Biomarkers can be used not only in the process of drug development, but also in assessment of individual patient's response to treatment. By evaluating the biomarker result, clinicians will be able to conclude whether the treatment has the desired effect or not. The BIPED classification categorizes biomarkers according to key parameters for evaluation and qualification of the utility of biomarkers. Those are: Burden of disease (B), Investigative (I), Prognostic (P), Efficacy of intervention (E) and Diagnostic (D) 3 .
In this review, we provide a systematic review of soluble biochemical markers (biomarkers) recently tested in clinical studies and cohorts. Furthermore, we highlight recent studies applying biomarkers in OA. In conclusion, we provide interpretation on how to classify biomarkers according to the BIPED criteria by differentiating each of the categories as of 2015.
Methods
The article consists of three parts. The first part summarizes peer reviewed papers on biomarkers published between April 1st 2014 and May 1st 2015. PubMed was used to search the time range, in combination with the MeSH terms BIOMARKER AND OSTEO-ARTHRITIS. From the initial search 115 articles were listed. Next, the list was further processed by only including publications written in English, reducing the list to 113; all were available as full text papers. Fourteen review articles were excluded from the list, leaving 99 original research articles for inclusion in the review process.
Each article was carefully studied and only articles including measurement of protein or peptide-based soluble biomarkers in serum, plasma, synovial fluid (SF) and urine of either OA patients or preclinical OA-associated models were included. Six articles describing the usage of biomarkers tested in animal models (Table S1) 92e96 and 41 describing the testing in clinical studies (Table I) were reviewed and tabulated in this review article. Fifty two articles were excluded because they were either: (1) not assessed in OA associated models/samples, (2) not soluble proteinderived biomarkers, or (3) not utilizing biomarkers in the study/ publication although. The second part of the article investigates the total number of publications publically available on each of the biomarkers described in the first part which reflects joint tissue turnover. The number of publications was investigated by searching on PubMed, using the biomarker name together with the MeSH term OSTEO-ARTHRITIS. Review articles were excluded. The limitation of the search was spelling mistakes and uncommon abbreviations, which may have led to unidentified publications. The numbers given in Table II are therefore an estimate, which should only be used as an information pointing towards the number of investigations published on individual biomarkers during the last decades.
The third part is a perspective (narrative) view on the usage of the biomarkers and how to use the BIPED classification to understand the utility of the biomarkers.
Biomarkers tested in clinical OA studies and cohorts
Different classes of biomarkers were tested in the 2014/2015 period targeting mainly two classes: (1) biomarkers of joint tissue turnover and (2) biomarkers of (pro-) inflammatory status. Table I summarizes the biomarkers tested in human OA samples. The BIPED classification in which the authors tested the hypothesis is given in the table.
During the past year several inflammatory biomarkers have been described, including cytokines, chemokines, or cell type markers important for OA pathology 4e8 . Another group of the newly identified biomarkers were biomarkers reflecting the turnover of the extracellular matrix (ECM) of the diseased cartilage 9e11 , while the remaining biomarkers targeted auto-antibodies, signaling molecules, or growth factors 12e19 . Many of these biomarkers were investigated based on the knowledge of OA pathology: Daghestani 4 worked from the hypothesis that inflammatory OA has a higher degree of activated macrophages, leading to a shedding of the macrophage cell markers: CD163 and CD14. In their study, they found these two markers indeed were increased and correlated to the severity and progression of OA symptoms 4 .
The hypothesis of another study was based on fractalkine (CX3CL1) playing a role in inflammation and chronic pain, and this study showed that CX3CL1 levels in serum and SF were correlated with WOMAC pain and WOMAC total scores 5 . Some biomarkers were identified using high-throughput methods like affinity proteomics and mass spectrometry. Affinity proteomics and antigen microarrays were used to detect auto-antibodies in human OA serum. Normally auto-antibodies are known from autoimmune disease like rheumatoid arthritis, but this study found autoantibodies against potassium channels, carbohydrate sulfotransferase, and interleukin-6 (IL-6) in human OA serum 14 .
Mass spectrometry was used to investigate tryptic digested cartilage slides from young, aging, and OA horses to identify ECM proteins and ECM fragments related to OA cartilage and non-aging cartilage. This study found disease-specific fibromodulin and biglycan peptides that were not linked to aging, and that additionally identified a number of fibronectin fragments with increased abundance in OA cartilage as tentative biomarkers 9 .
Selected reaction monitoring mass spectrometry, which enable measurements of several proteins in one sample, was used to identify clusterin and lubricin in human OA plasma as predictors of OA progression, with a prediction level equal to age 17 . In general the biomarkers identified were either identified as diagnostic biomarkers or burden of disease markers in serum, plasma, or SF. However, many of them were found in small sample sizes, and it is therefore important to further investigate these biomarkers in larger sample sizes. Additionally biomarkers measured in human SF were only measured in OA SF, as it is an invasive and unethical procedure to obtain SF from healthy control individuals. Biomarkers measured in SF were only correlated to serum or plasma levels and used to look at progression.
More established biomarkers that have previously been suggested as biomarkers that may correlate with features of OA, were tested in larger sample sizes and populations to further characterize the potential use of these biomarkers. Arendt-Nielsen and colleagues showed that the degradation fragment of CRP, CRPM, correlated with the degree of sensitization in a group of symptomatic OA patients (n ¼ 281) 20 , indicating a connection between pain sensitization and chronic inflammation. Carboxy-terminal cross-linked fragment of type II collagen (CTX-II) was measured in a large Japanese cohort of 1040 subjects. Here they found that CTX-II correlated with OA severity in the form of KL score in OA patients above 60 years of age. Another highly investigated marker is cartilage oligomeric matrix protein (COMP), which has been measured in a number of trials within this last year, with varying outcomes; it was shown to correlate with hand OA symptoms and increased AUSCAN scores, but not radiographic hand OA in cross-sectional study of 663 OA patients 21 . In another set of studies looking at traumatic KOA, no association was found between traumatic KOA severity and concentrations of COMP
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. Finally, Kim and colleagues looked at the correlation between COMP and OA in patients with synovitis, and found no association with effusion 23 . Probably the best tested biomarkers in OA are those reflecting joint tissue turnover such as urinary CTX-II or serum COMP, which both are believed to measure cartilage degradation 24 . One of the reasons why these may be of higher interest for OA is that these often have shown higher sensitivity and analyte stability, whereas cytokines is generally of more acute nature with short half-life 25 . Table II lists the biomarkers from Table I that measured tissue turnover and which have been tested in human OA studies or cohorts within the last 3 decades. Both CTX-II and COMP have been tested in more than 50 different studies, and may be the best validated OA biomarkers to date. However although they have been thoroughly tested the different datasets provide differential and somewhat contradictory results. This may be due to the type of OA patients tested, the design of the studies in respect to the hypothesis tested, and the statistical analyze conducted. This can make it rather difficult to qualify the biomarkers according to specific BIPED categories; however from a general view point these biomarkers can be classified as burden of disease, diagnostic and prognostic biomarkers.
When studying the list it stands out that most biomarkers measure cartilage degradation or bone resorption. What is lacking on the list are tests of cartilage formation/repair and synovial inflammation, which are also believed to play an important role in the pathogenesis of OA and are therefore imperative for a future diagnostic toolbox for OA. Examples of formation/repair biomarkers which have been developed and tested in human OA studies are CS846 26 and PIIANP 27, 28 . For these to be validated more clinical anabolic interventional studies with prospective biomarker strategies are needed. 
The BIPED criteria
The BIPED classification categorizes biomarkers according to key parameters for evaluation and qualification of the utility of biomarkers. Those are: Burden of disease (B), Investigative (I), Prognostic (P), Efficacy of intervention (E) and Diagnostic (D) 3 . Dbiomarkers are those that will enable identification of those patients with OA in the general population or specific phenotype of OA patients (e.g., metabolic vs trauma), whereas B-biomarkers are those which will aid in describing the disease burden or disease severity at a given point in time (e.g., metabolic status, degree of cartilage degradation). The B-biomarker is a snapshot of current status of the disease. Present diagnostic and burden of disease markers are radiographic images, as well as sign and symptoms recorded by the physician and/or patient. With respect to prognosis or prediction, FDA clearly distinguishes between these P markers. A prognostic biomarker is a baseline characteristic that categorizes patients by degree of risk for disease occurrence or progression of a specific aspect of a disease. A prognostic biomarker informs about the natural history of the disorder in that particular patient in the absence of a therapeutic intervention. It can be used as an enrichment strategy to select patients likely to have clinical events of interest or to progress rapidly.
A predictive biomarker is a baseline characteristic that categorizes patients by their likelihood of response to a particular treatment relative to no treatment. A predictive biomarker can be used as an enrichment strategy to identify a subpopulation likely to respond to a treatment intervention in a particular way. It may predict a favorable response or an unfavorable response (i.e., adverse event)." As such, The "P" (prognostic) biomarker is a marker which predicts future outcomes, such as the risk (odds) for structural progression, or other outcomes or events (e.g., joint inflammation, bone marrow lesion, and joint failure). An example would be that a P biomarker would identify those in most need of aggressive treatment, which then may be eligible for special care or intervention.
An example of a Prognostic biomarker can be found in the field of rheumatoid arthritis (RA), where the biomarker C1M was prognostic of structural progression 29 , while a combination of biomarkers were predictive of response to tocilizumab, an antiinterleukin 6 receptor treatment 29, 30 . A very important point for a clear differentiation between a prognostic and predictive biomarker is the needed level of qualification of the individual biomarkers. It is current BIPED description the predictive biomarker is an integrated part of the E category. An "E" biomarker is marker for measuring whether the drug is efficacious and can be used in Phase II dose-finding studies and, optimally, even prior to Phase II, for faster evaluation of potential efficacy. An example would be that an early change in a biomarker will predict whether a drug will be efficacious; that is meeting its clinical endpoint. This is in contrast to the predictive biomarker that will predict who will respond to a given treatment at baseline. In OA, it would be desirable to have available such biomarkers due to the long and vastly populated clinical trials, as it would allow for earlier decision-making.
The predictive E biomarker can used to determine which patients are specially eligible for a given treatment, such as herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2þ) and has spread into the lymph nodes, or is HER2þ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/ PR)-negative or have one high risk feature. This way, the diagnostic tool is linked to subsequent use of a treatment, in case of a positive test. Hence, a predictive E biomarker would most optimally be used to determine which kind of treatment strategy a patient would benefit from, for example an anti-inflammatory drug (e.g., IL-1 anti-IL1), an anti-resorptive drug 31 (e.g., Zoledronate), or a cartilage anabolic drug (e.g., FGF18) 32 .
It is important to note that FDA (and EMA) uses a different nomenclature when defining prediction and prognosis. According to the FDA, the main separating factor is that a prognostic biomarker provides you with an odds for progression, whereas a predictive biomarker would be used to decide the exact treatment regimen for individual patients, and would therefore have a significant impact on the patient's life. A predictive biomarker will often become a companion diagnostic 33 . Please find references to important guidelines and documents at the end of the article.
In 2011, Kraus et al. modified the BIPED characterization by adding a "S" for safety 34 . The purpose of the "S" biomarker was ideally to monitor the health status of the joint tissue or general cytotoxic status in response to treatment. One could imagine that a relative ratio between an "E" and "S" biomarker could provide a risk/benefit ratio for a drug in a trial. Finally, an "I" biomarker is a marker of which not sufficient information is available yet to allow its inclusion in one of the other categories. As no biomarkers have been qualified as biomarkers for OA, this category covers the majority of biomarkers tested in OA.
It is important to test and validate a biomarker to a hypothesis that covers just one of the classifications or test the classification individually. Although we in this paper and other in other papers try to categorize the biomarkers according to the BIPED there is still some question marks regarding the categorization, as biomarker most cohorts are tested retrospectively and no prospectively for exactly validating a BIPED hypothesis. Also predictiveness toward treatment efficacy still needs to be tested, as there are only trials for DMOARDs and even fewer (if any) testing biomarkers as outcome measure. A good biomarker would only has to be validated for one of the classifications other than "I" to qualify for the clinical usage.
Ongoing initiatives for validating and qualifying biomarkers
The issues in understanding OA patho-physiology and subsequent translational application of in vitro diagnostics of such understanding in drug development are large and complex, Independent efforts have led to slow and insufficient clinical progress, as outlined above. Also the use of drug development tools (DDT) is of particular interest, and biomarkers for e.g., progression would be an advantage for patient selection in interventional trials. Some of these challenges can be best addressed and the obstacles be overcome by Public-Private-Partnerships (PPP) of engaged, knowledgeable, and complimentary industrial, academic, patient and governmental experts who can provide innovative and viable solutions. Considering the scale of the problem and societal impact, there remains a major unmet need as current treatments are predominantly restricted to symptomatic relief or costly and invasive surgical intervention.
Multiple reasons have been identified as underlying causes of past clinical failures:
Limited understanding of OA pathogenesis. Emerging data suggest OA is a heterogeneous disease with a variety of pathophysiologic drivers, some of which are amenable to pharmacologic intervention, and some of which are expected to be less so. Variable disease course. The majority of an unselected OA population do not progress radiographically or clinically in a given 2 year window; companies have not had the tools or knowledge base to prospectively identify patients at risk of progression who stand to benefit the most from effective therapies. Absence of personalized medicine mindset. Clinical development plans have frequently used a 'one size fits all' approach rather than matching mechanism of action to specific OA patient subpopulations and using specific DDTs. Reliance on relatively insensitive endpoints. X-ray-based joint space narrowing (the current standard endpoint to demonstrate disease modification) is insensitive, tends to be slowly evolving and does not allow visualization of the tissue most associated with the disease (cartilage). Lack of a qualification strategy for the applied biomarkers and DDTs in a clinical setting and for diagnosis.
In PPP consortia, these points are addressed in close collaboration of different academic and industry partners. The FNIH/OARSI initiative on OA biomarkers and imaging 35 has just presented first comprehensive data on imaging and biochemical markers out of the analysis (http://oarsi.org/sites/default/files/docs/2015/fnih_ 2015_pre_congress_workshop_final.pdf) and also reference intervals for healthy subjects for the selected biomarkers
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. A phase 2 of the initiative will further substantiate the findings and characterize and validate biomarkers in different clinical cohorts. In Europe the Innovative Medicine Initiative (IMI) has started to bring further knowledge in the field. In both initiatives several topics will be addressed:
Consolidated existing complementary OA data sets (public and private) Definition and characterization of OA patient subsets, also using bioinformatics Identification of novel biomarkers for OA Biochemical marker assay platform validation and development Validation of biochemical markers and next generation imaging technologies in a cohort of OA patients User-friendly interface where data can be publically accessed and analyzed (e.g., OAI) Work with regulators to finalize guidance and initiate regulatory biomarker qualification process Lastly the D-BOARD consortium, an EU funded PPP initiative, is working on identification and validation of novel biomarkers and pushing those forward toward qualification, by applying the BIPED categories for hypothesis testing (http://www.d-board.eu/dboard/ index.aspx).
Conclusion
Work is continuing on testing biomarkers in OA and will need to continue in the future, as present data do not reach and answer the medical need in the field. However much of validation and qualification work is halted by the lack designated biomarker studies and successful drug trials. Although interesting biomarkers have been tested in 2014/2015, little clinical validation or qualification studies have been presented. Thus there is still a huge, unmet medical need to identify, test, validate and qualify novel and wellknown biomarkers. A pre-requite for this is better characterization and classification of biomarkers to their needs, which may not be reached before understanding of OA phenotypes has been much improved. However this needs to be substantiated and supported in a broader context including a reflection on the guidelines provided by the regulatory authorities, which extent outside of this review. The running and upcoming PPP initiatives are expected to select and push the best biomarkers forward towards qualification.
Documents of interest from the regulators
Following links provide some of the guidelines on qualification and approval routes published by the regulators, which may be of great value for biomarker development for use drug development and personalized medicine and health care. 
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